NovoCure director Timothy Scannell retires

NovoCure Ltd (NVCR) reported that director Timothy Scannell has retired from its Board of Directors, and his board seat was formally vacated in accordance with the company’s Articles of Association effective September 2, 2026.

Rhea-AI Filing Summary

NovoCure Ltd (NVCR) reported that director Timothy Scannell has retired from its Board of Directors, and his board seat was formally vacated in accordance with the company’s Articles of Association effective September 2, 2026.

The company stated that Mr. Scannell’s retirement after five years of service did not result from any disagreement with NovoCure or its management.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Effective retirement date: September 2, 2026 Years of board service: 5 years Form type: Form 8-K

3 metrics

Effective retirement date September 2, 2026 Date Timothy Scannell’s board seat was formally vacated

Years of board service 5 years Length of service by director Timothy Scannell before retirement

Form type Form 8-K Current report disclosing director retirement

Key Terms

Articles of Association, Emerging growth company, Inline XBRL

3 terms

Articles of Association regulatory

"his seat was formally vacated pursuant to the Company’s Articles of Association"

A company's articles of association are its written rulebook that sets how the business is run, how decisions are made, and what rights owners and directors have—covering voting, meetings, appointment and removal of directors, share classes and dividend policies. For investors, these rules matter because they determine how easily control can change, what protections minority owners have, and how corporate actions (like issuing new shares or changing leadership) are approved, much like a home’s bylaws shaping what residents can and cannot do.

Emerging growth company regulatory

"Emerging growth company o"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Inline XBRL technical

"Cover Page Interactive Data File (embedded within the Inline XBRL document)"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board change did NovoCure Ltd (NVCR) disclose on September 2, 2026?

NovoCure disclosed that director Timothy Scannell retired from the Board of Directors, and his seat was vacated pursuant to the company’s Articles of Association, effective September 2, 2026.

Did Timothy Scannell’s retirement from NovoCure’s (NVCR) board involve any disagreement?

No. NovoCure stated that Mr. Scannell’s retirement from the board after five years of service did not result from any disagreement with the company or its management.

What is the effective date of the board change reported by NovoCure (NVCR)?

The effective date of the board change is September 2, 2026, when director Timothy Scannell’s retirement took effect and his board seat was formally vacated.

Who signed NovoCure’s (NVCR) report about the director’s retirement?

The report was signed on behalf of NovoCure by Christoph Brackmann, who is identified as the company’s Chief Financial Officer, dated September 9, 2026.

Which security of NovoCure Ltd (NVCR) is registered on a national exchange?

NovoCure lists its Ordinary Shares, no par value, under the trading symbol NVCR on The Nasdaq Stock Market LLC, as stated in the report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 07:03 AM EDT Accepted by SEC EDGAR 09/09/2026 - 07:02 AM EDT Learn about SEC filing dates

0001645113false00016451132026-08-012026-09-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

September 2, 2026

Date of Report (date of earliest event reported)

NovoCure Limited

(Exact name of registrant as specified in its charter)

Jersey			001-37565						98-1057807
(State or other jurisdiction of incorporation or organization)			(Commission File Number)						(I.R.S. Employer Identification No.)
No. 4 The Forum, Grenville Street			St. Helier			Jersey			JE2 4UF
(Address of Principal Executive Offices)									(Zip Code)

+44 (0) 15 3475 6700

Registrant's telephone number, including area code

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Ordinary Shares, no par value			NVCR			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

o

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) Timothy Scannell, a current director of NovoCure Limited (the “Company”), has retired from the Board and his seat was formally vacated pursuant to the Company’s Articles of Association effective September 2, 2026. Mr. Scannell's retirement from the Board after five years of distinguished service did not result from any disagreement with the Company or its management.

Item 9.01    Financial Statements and Exhibits.

(d)    Exhibits

Exhibit No.			Description
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NovoCure Limited

(Registrant)

Date: September 9, 2026

By: /s/ Christoph Brackmann  

Name: Christoph Brackmann

Title: Chief Financial Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.3 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.3 KB